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Abstract
Imidazoline receptor agonists are one of the groups of contemporary antihypertensive drugs with the pleiotropic car-
diovascular effects. In this review, the historical, physiological, pathophysiological aspects concerning imidazoline 
receptor agonists and possible mechanisms for their participation in endothelioprotection were considered. Illuminated 
the molecular biology of each subtype of imidazoline receptors and their significance in the pharmacological correction 
of cardiovascular disease.
IR type 1 are localized in the brain nucleus, carrying out the descending tonic control of sympathetic activation, as well 
as in the endothelial cells of the vessels and kidneys. Their activation leads to a decrease in blood pressure, slowing 
the remodeling of the vascular wall and increasing sodium nares. IR type 2 is expressed predominantly in the adrenal 
gland, fat and muscle tissues. The physiological effects of their stimulation are associated with an increase in glucose 
utilization by peripheral tissues. IR type 3 are mainly present in pancreatic cells and are associated with the regulation 
of insulin secretion. Their stimulation leads to an increase in insulin liberation. Thus, IR agonists are able to improve 
endothelial function through various mechanisms, including blood pressure reduction, improvement in metabolic pro-
file, and direct positive effects on the vascular wall.
Current information on the pharmacological effects of this group compounds allows us to conclude that they are a 
promising group for correcting endothelial dysfunction and complications associated with it.
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Introduction
The permanent growth of cardiovascular diseases and 
the socioeconomic damage they cause dictates the ne-
cessity for constant improvement of strategies aimed at 
the prevention and treatment of this nosological group. 
Improving the data about the pathogenetic basis of ather-
ogenesis and endothelial dysfunction allows developing 
existent and creating new strategies for the cardiovascu-
lar pathology prevention and correction.
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Modern arsenal of remedies for the pharmacotherapy of 
essential hypertension and associated vascular injury can 
affect various pathophysiological contours: renin- angio-
tensin-aldosterone system, intracellular calcium concen-
tration, sympathetic tone, lipid metabolism. A certain ad-
vantage is possessed by drugs having application points in 
several pathological cascades. Drugs which can be applied 
to several pathological cascades have certain advantage. 
These drugs include imidazoline receptor (IR) agonists.
History of discovery and general 
information about imidazoline 
receptors
The use of IR agonist in medical practice has a long his-
tory. In 1945, the cases of hypotension among teenagers 
and children who had been taking nasal congestients of 
imidazoline nature led to the synthesis of a number of 
drugs with antihypertensive activity, the first of which 
was clonidine. Then it was found that the mechanism of 
their action is caused by the central sympatholytic activi-
ty (Lowry et al. 2014). Further studies have shown that 
α2-adrenergic receptors (α2- AR) are their primary target 
(Timmermans et al. 1981).
However, in a comparative study of the derivatives of 
β-phenylethylamine and imidazoline activity Ruffolo et 
al. (1982) obtained the evidence that the binding sites for 
these compounds are not the same. This indicated either 
the existence of different binding sites on α2-AR, or the 
interaction of imidazoline derivatives with some other 
receptor. Since the application of imidazoline derivatives 
to the lateral reticular nucleus without a2-adrenoreceptors 
caused a decrease of blood pressure, it was predicted that 
there are specific receptors with a resemblance for a given 
chemical group. (Bousquet et al. 1986, 1989).
A further search led to the discovery of their endogen-
ous ligand of agmatin, which is decarboxylated arginine 
(Li et al. 1994). A study of its phenotypic effects has for-
med the idea of the existence of three types of IR. While 
the hypotensive effect is mediated by I1R (Ernsberger et 
al. 1995), I2R and I3R mainly control metabolic proces-
ses. Presently, only the gene of the first type receptors has 
been cloned, therefore, detailed information on the do-
main and molecular structure was obtained only for them.
Imidazoline receptors type 1
According to existing ideas, imidazoline receptors of type 
1 (I1R) being localized in the ventrolateral region of the 
medulla oblongata, are responsible for tonic and reflex 
control of the sympathetic nervous system.
The I1R molecule is encoded by the NISCH gene (also 
known as I-1; IR1; IRAS; hIRAS) which is located on 
third chromosome and widely expressed in many body 
tissues but most active in the prefrontal cortex, epiphysis 
(at night), tonsils, pituitary gland, kidneys, prostate and 
testes (Fagerberg et al. 2014) (Fig. 1).
The protein product of the NISCH gene (Video 1), 
also called nischarin (Zhang et al. 2006), is located in 
the cytosol, cytoplasm, endosomes, or cytoplasmic 
membrane and, depending on localization, can partici-
pate in the processes of intracellular signal transmissi-
on, formation of the cytoskeleton (binding integrins), 
regulation of apoptosis, proliferation, cell migration and 
some others (MGC 2002). It is the transmembrane form 
that performs the receptor function and is the classical 
I1R- receptor.
Connecting of this form with ligands leads to con-
formational changes which promote its interaction with 
phosphatidylinositol and phosphorylation of mitogen- ac-
tivated protein kinases (MAPK-1 and MAPK-3). An im-
portant molecular effect of I1R is its ability to suppress the 
activation of GTPase Rac1 triggering cell death processes 
(Alahari et al. 2000).
The arginine decarboxylase enzyme synthesizing ag-
matin from the amino acid L- arginine is widely expres-
sed in brain. To some authors point of view, agmatine, 
synthesized locally, is an endogenous imidazoline recep-
tor agonist, and It is associated with neurotransmitter con-
trol of descending sympathetic activation (Li et al. 1994).
It is considered that besides the participation in the re-
gulation of vascular tone, neurogenic stimuli mediated by 
I1R also control adrenal function (increasing the release of 
catecholamines) and kidneys (reducing natriuresis) (Smy-
th et al. 1999). In addition, broad expression of imidazo-
line receptors in the kidney and endothelium allows them 
directly influence on the functional state of these tissues.
Imidazoline receptors type 2
I2R mediates the utilization of glucose by muscle tissue 
(through the activation of AMPK) (Lui et al. 2010, Chang 
et al. 2010). It has also been shown that this type of recep-
tors has an affinity for guanidine and guanidino-like com-
pounds, one of which is metformin. It is considered that 
most of metabolic effects of metformin are mediated by its 
antagonism to these receptors. Thus, the use of selective 
I2R - agonist BU224 neutralized such its effects as glycemia 
decrease, sensitivity of cells to insulin increasing, and the 
adrenal secretion of β-endorphin - a molecule that increases 
glucose uptake by peripheral tissues (Lee et al. 2011).
It has been shown that the amiloride injection to rats 
with streptozotocin-induced diabetes mellitus highly neu-
tralizes the pharmacological effects of metformin. This 
effect is explained by its metformin’s affinity for I2R, as a 
guanidine structure compound. Based on the fact that I2R 
with high (placenta) and low (brain) affinity for amiloride 
were identified in humans, it was suggested that I2R are 
heterogeneous and represented by types A and B (Dia-
mant et al. 1992, Miralles et al. 1993). I2AR controls the 
release of β-endorphin (blocked by low concentrations of 
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Figure 1. Tissue expression of the NISCH gene (Fagerberg et al. 2014)
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Video 1. Graphic structure of I1R (Madej et al. 2014)
amiloride), and I2BR directly regulates tissue utilization 
of glucose (blocked by high concentrations of amiloride). 
Imidazoline connecting domains were found on MAO-A 
and MAO-B enzymes (Tesson et al. 1999). It’s possible 
that such psychotropic effects of imidazolines as modula-
tion of nociception, dependence and addiction formation 
are determined by their blocking effect on these enzymes, 
as they participate in the mediator systems of brain func-
tion (Gulati et al. 2009, Li et al. 2011).
Imidazoline receptors type 3
The agonist’s imidazoline receptors ability to increase 
insulin concentration has prompted researchers to detai-
led analysis of the nature of this process. As a result of a 
series of experiments on cell cultures of insulinoma RIN-
5AH, it was shown that the insulin secretagogue function 
of pancreatic β-cells is increased by the action of imida-
zoline compounds even with selective blocking of I1R and 
I2R. This research has indicated the presence of another 
imidazoline-sensitive receptor and initiated the investi-
gation of I3R (Morgan et al. 1999; Olmos et al. 1994). 
Since the addition of an activator of K+-ATP-dependent 
diazoxin channels prevents insulinolysis, it is conside-
red that I3R performs its function through regulation of 
K+ and Ca2+ concentrations of Langerhans cells. Later, 
β-carboline Harmane was found as its selective agonist 
(Morgan et al. 2003).
Endothelial dysfunction
The concept of endothelial dysfunction as the central 
element in the development of cardiovascular pathology 
allows us to consider endotheliocytes as one of the main 
targets for the therapy and prevention of arterial hyper-
tension, atherosclerosis, atherothrombosis and related 
diseases. It is known that the ability to produce the wi-
dest spectrum of biologically active substances and the 
strategically important localization of the endothelial mo-
nolayer determine its participation in the control of he-
modynamics, rheology of blood, hemostasis, neovascu-
logenesis and inflammation. In connection with this, ED 
leads to vasoconstriction, thrombophilia, impairs vascular 
wall permeability and its leukocyte infiltration, activation 
of oxidative stress and lipid peroxidation, the appearan-
ce of anomalies in the architectonics of the vasculature. 
The pharmacodynamic effects inherent in the imidazoline 
receptor agonists are capable of conditioning the endot-
helioprotective effect through a number of fundamentally 
different mechanisms:
1) Effect on vascular tone:
Violation of the endothelium vasoregulatory function 
leads to the appearance of permanent vasoconstriction. At 
the same time, hypertension is the factor contributing to 
damage to the endothelial monolayer. As a result, a uni-
que vicious circle is created, the rupture of which is one 
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of the important tasks of pharmacotherapy. The central 
effects of imidazoline receptor agonists, realizing through 
relaxation of sympathetic tone, are considered as a basis 
for their hypotensive action. However, the reduction in 
vascular tone is also maintained when imidazolines act 
on the isolated aortic ring of rats. This fact indicates the 
presence of a peripheral component in their hypotensive 
effect. Wherein, this effect is blocked by the preliminary 
injection of BU224, it means it has been mediated by I2R. 
Besides, when imidazoline receptor agonists were used 
in spontaneously hypertensive rats, vasodilation of perip-
heral arterioles was observed (Chen et al. 2014). The me-
chanism of this phenomenon is caused by expression on 
endothelial cells of I1R, phosphatidylinositolkinase (PI3K) 
activity of which leads to activation of eNOS (Joshi et al. 
2007; Maltsev et al. 2013). It also matters that the activa-
tion of I2R can reduce the voltage-dependent activation of 
Ca2+-channels of neurons innervating the vessels (Kim et 
al. 1999). Finally, the antihypertensive effect of imidazo-
line receptor agonists may be due to their nephroprotec-
tive and natriuretic activity (Smyth et al. 1999, Elkomy et 
al. 2018) (Fig. 2).
2) Effect on the metabolic profile:
A complex of metabolic abnormalities manifested by obe-
sity, insulin resistance and hyperinsulinemia can be com-
bined in one term - the metabolic syndrome. This disorder 
is a significant risk factor of the development and progres-
sion of cardiovascular diseases.
At the same time, as a result of hyperglycemia, exces-
sive glycosylation of proteins, disruption of intracellular 
metabolism and disruption of cell function occurs. With 
considering the peculiarities of localization of endothe-
liocytes, it is not surprising that they are the most vulne-
rable to long-term increase in glucose level (Tziomalos et 
al. 2010; Polovina et al. 2014). Clinical investigations of 
imidazoline receptor agonists in groups of patients, besi-
des the antihypertensive effects, have demonstrated their 
effectiveness in correction of the metabolic syndrome. 
Thus,  the use of the imidazoline receptor agonist - moxo-
nidine in patients with obesity and metabolic syndrome 
led to a statistically significant increase in the insulin sen-
sitivity index by 21% compared with placebo. (Haenni et 
al. 1999). This effect is due to both hypoglycemic acti-
on associated with I2R and I3R (Fig. 2), and the effect on 
adipocytokines, such as adiponectin as well. (Zuo et al. 
2015; Weiss et al. 2015)
3) Direct effect on endothelial cells:
With considering the ability of imidazoline receptors to 
inhibit apoptosis and inflammatory activation (mainly due 
to inhibition of Rac1), it seems logical to suppose that 
Figure 2. Ways of endothelioprotection with the participation of imidazoline receptor agonists. ED - endothelial dysfunction; EC - 
endothelial cells; I1R - imidazoline receptor type 1; I2R - imidazoline receptor type 2; imidazoline receptor type 3.
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these effects are also realized in endothelial cells. It is 
important that, with the action of imidazoline agonists, 
a change in the cellular homeostasis of endotheliocytes 
leads to a decrease in the concentration of molecules such 
as plasminogen activator inhibitor and thrombomodulin 
(Krespi et al. 1998).
From the point of view of direct effect on endothelio-
cytes, the above-mentioned ability of imidazoline com-
pounds to effect on eNOS is the most important, since the 
NO-producing function of the endothelium mediates not 
only the vasodilation, but also such processes as regula-
tion of the aggregate state of blood and reduction of the 
stiffness of the vascular wall (Fig. 2).
Conclusion
Thus, pharmacotherapy with the use of imidazoline re-
ceptor agonists has not only an antihypertensive, but also 
an endothelioprotective purpose as well. Considering the 
presently available ideas, the described positive effects of 
imidazoline agonists allow us to view them as effective 
measures with pleiotropic effects and potentially impro-
ving the removed prognosis of patients.
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